Head of Investor Relations

Lycia Therapeutics South San Francisco Updated 18 November 2026
PharmaBiotechClinical ResearchRegulatory Affairscroinform

Job description

Lycia Therapeutics (Nasdaq: LYCA) is a clinical-stage biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune, inflammatory, and allergic conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In October 2026, Lycia completed an initial public offering, and its common stock now trades on the Nasdaq Global Select Market under the ticker symbol “LYCA.” Lycia is headquartered in South San Francisco. Visit https://lyciatx.com/ for more information. Lycia is hiring a Head of Investor Relations to build the function following the company's initial public offering. Title will reflect the experience of the person hired. The role reports to the Chief Financial Officer and works closely with the Chief Executive Officer and the executive team. This leader will manage Lycia's relationships with investors, sell-side analysts and banking partners, and will shape how the company's science, clinical progress and financial position are communicated to the market. It is a hands-on role for someone who wants to build a public company IR program from the ground up. Key responsibilities Build and lead Lycia's investor relations strategy, annual IR activities and investor targeting program to develop a high-quality, long-term institutional shareholder base, and monitor shareholder composition, trading activity and investor sentiment. Own the equity story and investor narratives and adapt the investment case and corporate presentation for different investor audiences without compromising scientific precision. Lead planning process for clinical data releases, including advising on disclosure timing, preparing press releases and presentation materials, ensuring key opinion leader participation and post-release investor follow-up, in coordination with clinical, regulatory and legal teams. Plan and execute investor and disease-specific conferences, non-deal roadshows, investor and analyst events and key opinion leader events, and prepare management for these events. Lead communications for quarterly reporting incorporating clinical, regulatory, financing and corporate milestones, including press releases, key messages and investor Q&A, partnering with Legal and Finance on disclosure controls and review of external materials. Partner with the Chief Business Officer on corporate communications, owning investor- facing content on the website, press releases and corporate social media, and contributing to broader media, partner and brand messaging so that narrative and positioning stay consistent across audiences. Build relationships with sell-side analysts, including in-depth review of models and leading strategic coverage expansion beyond current analysts. Lead competitive intelligence and synthesize insight from investors, analysts, key opinion leaders and other market participants to sharpen positioning, test assumptions and inform program strategy, consistent with Lycia's scientific and compliance processes. Apply AI and digital tools to literature and competitor synthesis, landscape monitoring, message testing and investor meeting tracking. Proactively bring insights to management. Qualifications 10 or more years of experience in biotechnology investor relations, capital markets, equity research, investment banking or an IR advisory firm, including direct experience leading IR at a public company or advising public company management teams. Track record of supporting clinical readouts, financings and other market-moving events. Established relationships with healthcare-focused institutional investors, sell-side analysts and banks. Working knowledge of SEC disclosure requirements, Regulation FD and public company reporting processes. Scientific fluency sufficient to explain a novel therapeutic platform and clinical data credibly to specialist investors. Strong writing, judgment and executive presence, and comfort operating as a hands-on, one-person function working closely with the management team. Bachelor's degree required. An advanced degree in the life sciences or business is preferred.

Stand out for this role

NoxPharm tailors your CV to this job description by aligning your experience with the role requirements and terminology. Built for pharma & life sciences.

Tailor my CV now — free to try